Incyte Corp. (INCY)
105.39
+2.16
(+2.09%)
USD |
NASDAQ |
Jun 10, 16:00
105.38
-0.01
(-0.01%)
After-Hours: 06:53
Incyte Enterprise Value : 17.10B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 17.10B |
| June 09, 2026 | 16.66B |
| June 08, 2026 | 16.15B |
| June 05, 2026 | 16.49B |
| June 04, 2026 | 16.27B |
| June 03, 2026 | 15.61B |
| June 02, 2026 | 14.47B |
| June 01, 2026 | 15.14B |
| May 29, 2026 | 15.37B |
| May 28, 2026 | 15.52B |
| May 27, 2026 | 15.49B |
| May 26, 2026 | 15.44B |
| May 22, 2026 | 15.45B |
| May 21, 2026 | 15.50B |
| May 20, 2026 | 15.43B |
| May 19, 2026 | 15.14B |
| May 18, 2026 | 15.06B |
| May 15, 2026 | 15.08B |
| May 14, 2026 | 15.54B |
| May 13, 2026 | 15.78B |
| May 12, 2026 | 15.84B |
| May 11, 2026 | 16.08B |
| May 08, 2026 | 15.73B |
| May 07, 2026 | 15.57B |
| May 06, 2026 | 15.99B |
| Date | Value |
|---|---|
| May 05, 2026 | 15.51B |
| May 04, 2026 | 15.45B |
| May 01, 2026 | 15.40B |
| April 30, 2026 | 15.07B |
| April 29, 2026 | 15.84B |
| April 28, 2026 | 15.57B |
| April 27, 2026 | 15.16B |
| April 24, 2026 | 14.95B |
| April 23, 2026 | 15.11B |
| April 22, 2026 | 15.37B |
| April 21, 2026 | 15.26B |
| April 20, 2026 | 15.40B |
| April 17, 2026 | 15.58B |
| April 16, 2026 | 15.08B |
| April 15, 2026 | 15.44B |
| April 14, 2026 | 15.56B |
| April 13, 2026 | 15.13B |
| April 10, 2026 | 15.23B |
| April 09, 2026 | 15.41B |
| April 08, 2026 | 15.20B |
| April 07, 2026 | 14.76B |
| April 06, 2026 | 14.99B |
| April 02, 2026 | 15.20B |
| April 01, 2026 | 14.88B |
| March 31, 2026 | 14.84B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 38.82B |
| BioMarin Pharmaceutical, Inc. | 10.08B |
| Vertex Pharmaceuticals, Inc. | 105.47B |
| Mirum Pharmaceuticals, Inc. | 5.665B |
| Biogen, Inc. | 30.95B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 303.33M |
| Revenue (Quarterly) | 1.273B |
| Total Expenses (Quarterly) | 969.35M |
| EPS Diluted (Quarterly) | 1.467 |
| Gross Profit Margin (Quarterly) | 90.46% |
| Profit Margin (Quarterly) | 23.83% |
| Earnings Yield | 6.71% |
| Operating Earnings Yield | 6.78% |
| Normalized Earnings Yield | 6.131 |